[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ureteral-stent-placement\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ureteral-stent-placement":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100334793","early-phase-1-nsaids-stent-study-100334793",false,"NCT03638999","NSAIDs Stent Study","A Prospective, Randomized, Pilot Study of Preoperative Anti-Inflammatory Therapy for Ureteral Stent Symptoms","Inclusion Criteria:\n\n* Over 18 years of age and willing and able to provide informed consent\n* Patients with renal urolithiasis planning to undergo ureteral stent placement following ureteroscopic manipulation\n\nExclusion Criteria:\n\n* Patients requiring a bilateral stone procedure.\n* Patients on a chronic non-steroidal anti-inflammatory drugs (NSAIDs) including Aspirin defined as any NSAIDs use for more than fifteen days within thirty days prior to the procedure. Exception: use of daily Aspirin 81 mg is allowed.\n* Patients on any steroid therapy.\n* Patients with prescription anti-inflammatory drugs.\n* Patients with gastrointestinal ulcers.\n* Patients with ureteral obstruction or stricture unrelated to stone disease.\n* Patients with active urinary tract infection as evidence of untreated positive urine culture obtained prior to the procedure (as part of pre-operative testing).\n* Patients with preexisting indwelling ureteral stent\n* Patients who are pregnant or lactating.\n* Patients with renal or liver impairment.\n* Patients with concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would render the patient inappropriate for enrollment.","ALL","18 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","This is a pilot study to (1) evaluate the effect of Ketorolac on inflammatory response and its impact on stent related symptoms in patients undergoing stent placement procedure and (2) assess feasibility of recruitment, randomization, assessment procedures and implementation of the study intervention.",[26,27],"Ureteral Stent Placement","Kidney Stone","RECRUITING","2025-12-15",{"date":31,"type":32},"2025-12-22","ACTUAL",{"date":34,"type":32},"2018-07-31",{"date":36,"type":20},"2027-10",{"name":38,"class":39},"Washington University School of Medicine","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":40},"100604083","phase-4-assessing-the-efficacy-of-indocyanine-green-for-ureter-identification-during-robot-assisted-surgery-in-advanced-stage-endometriosis-100604083","NCT07144904","Assessing the Efficacy of Indocyanine Green for Ureter Identification During Robot-Assisted Surgery in Advanced-Stage Endometriosis","A Side-Randomized, Self-Controlled Trial Assessing the Efficacy of Indocyanine Green Fluorescence Imaging for Intraoperative Ureter Identification During Robot-Assisted Single-Site Surgery in Advanced-Stage Endometriosis","Inclusion Criteria:\n\n* Stage III or IV endometriosis (rASRM classification)\n* Planned robotic transabdominal endometriosis excision with or without hysterectomy.\n\nExclusion Criteria:\n\n\\- Subjects who are part of a vulnerable population will be excluded including those who are prisoners, younger than 18 years old, pregnant, individuals with mental disabilities or cognitive impairment.","FEMALE",{"count":50,"type":20},40,[52],"PHASE4","The goal of this side-randomized, self-controlled trial, 1-site study is to explore the efficacy of Indocyanine Green Fluorescence (ICG) for Intraoperative Ureter Identification During Robot-Assisted Single-Site Surgery in Advanced-Stage Endometriosis.\n\nResearchers will perform temporary ureteral stent using indocyanine green fluorescence for intraoperative ureteral identification on either the left or right side of subjects who are undergoing a robotic assisted transumbilical resection of advanced endometriosis.\n\nParticipants will be randomized to receive ICG-assisted ureteral identification on either the left or right side. Randomization will be conducted using a computer-generated block randomization method.\n\nThe primary aim is to determine whether ICG-assisted ureter visualization can reduce operative time for endometriosis resection and ureterolysis, and minimize the risk of ureteral injury.\n\nSecondary objectives are to assess the feasibility and safety of temporary ureteral ICG stenting for intraoperative ureter identification in advanced endometriosis.",[55,56,57,58,59,60,26,61,62],"Indocyanine Green (ICG)","Robotic Surgical Procedure","Deep Infiltrating Endometriosis (DIE)","Endometriosis Pelvic","Endometriosis (Diagnosis)","Endometriosis of the Cul-de-sac","Ureteral Injury","Endometriosis Ovaries",[64,65,66,67,68],"ureteral stent placement","indocyanine green","endometriosis","robotic surgery","ureteral identification","NOT_YET_RECRUITING","2025-08-20",{"date":72,"type":32},"2025-08-28",{"date":74,"type":20},"2025-10-01",{"date":76,"type":20},"2026-03-15",{"name":78,"class":39},"Baylor College of Medicine"]